Enovis (ENOV) Expected to Announce Quarterly Earnings on Thursday

Enovis (NYSE:ENOV) is expected to be issuing its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of $0.67 per share and revenue of $538.6120 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 6, 2025 at 8:30 AM ET.

Enovis (NYSE:ENOV) last issued its quarterly earnings data on Monday, January 8th. The company reported $0.59 earnings per share (EPS) for the quarter. The firm had revenue of $383.81 million for the quarter. Enovis had a negative net margin of 37.80% and a positive return on equity of 6.78%. On average, analysts expect Enovis to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Enovis Stock Down 2.8%

Shares of ENOV opened at $31.95 on Thursday. The firm has a market cap of $1.83 billion, a P/E ratio of -2.24 and a beta of 1.69. Enovis has a 12-month low of $25.47 and a 12-month high of $49.83. The company’s 50-day moving average price is $31.39 and its 200 day moving average price is $31.54. The company has a current ratio of 2.25, a quick ratio of 1.15 and a debt-to-equity ratio of 0.53.

Wall Street Analysts Forecast Growth

ENOV has been the topic of several research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Enovis in a report on Wednesday, October 8th. Canaccord Genuity Group reduced their price objective on shares of Enovis from $70.00 to $58.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Evercore ISI reduced their price objective on shares of Enovis from $48.00 to $46.00 and set an “outperform” rating on the stock in a report on Tuesday, July 8th. Needham & Company LLC reduced their price objective on shares of Enovis from $57.00 to $49.00 and set a “buy” rating on the stock in a report on Thursday, August 7th. Finally, UBS Group cut their price target on shares of Enovis from $65.00 to $57.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $51.00.

Insider Transactions at Enovis

In related news, SVP Bradley J. Tandy acquired 3,200 shares of the stock in a transaction dated Friday, August 22nd. The stock was acquired at an average cost of $31.41 per share, with a total value of $100,512.00. Following the completion of the transaction, the senior vice president owned 43,515 shares in the company, valued at $1,366,806.15. This represents a 7.94% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Damien Mcdonald acquired 6,457 shares of the stock in a transaction dated Thursday, September 11th. The shares were bought at an average cost of $30.97 per share, with a total value of $199,973.29. Following the completion of the transaction, the chief executive officer owned 102,753 shares of the company’s stock, valued at approximately $3,182,260.41. This represents a 6.71% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders purchased 12,157 shares of company stock valued at $374,760. 2.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Enovis

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC boosted its holdings in Enovis by 125.4% in the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after purchasing an additional 707 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in Enovis by 578.2% in the second quarter. Tower Research Capital LLC TRC now owns 4,347 shares of the company’s stock valued at $136,000 after purchasing an additional 3,706 shares in the last quarter. State of Wyoming boosted its holdings in Enovis by 555,600.0% in the second quarter. State of Wyoming now owns 5,557 shares of the company’s stock valued at $174,000 after purchasing an additional 5,556 shares in the last quarter. Empowered Funds LLC boosted its holdings in Enovis by 13.0% in the first quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock valued at $249,000 after purchasing an additional 749 shares in the last quarter. Finally, Gabelli Funds LLC acquired a new position in Enovis in the second quarter valued at approximately $289,000. 98.45% of the stock is owned by institutional investors and hedge funds.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.